Resultados da busca - Samuel DePrimo

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy por Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp

Obter o texto integral

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy por Andrew Blauvelt, Yanqing Chen, Patrick J. Branigan, Xuejun Liu, Samuel DePrimo, Brice E. Keyes, Monica Leung, Steven Fakharzadeh, Ya-Wen Yang, Ernesto J. Muñoz-Elías, James G. Krueger, Richard G. Langley

Obter o texto integral

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534 por Xiaohua Xue, Aimee De Leon-Tabaldo, Rosa Luna-Roman, Glenda Castro, Michael Albers, Freddy Schoetens, Samuel DePrimo, Damayanthi Devineni, Thomas Wilde, Steve Goldberg, Thomas Hoffmann, Anne M. Fourie, Robin L. Thurmond

Obter o texto integral

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534 por Xiaohua Xue, Aimee De Leon-Tabaldo, Rosa Luna-Roman, Glenda Castro, Michael Albers, Freddy Schoetens, Samuel DePrimo, Damayanthi Devineni, Thomas Wilde, Steve Goldberg, Olaf Kinzel, Thomas Hoffmann, Anne M. Fourie, Robin L. Thurmond

Obter o texto integral